The past week saw four IPOs produce insignificant returns. All four deals finished the week at or above the offer price, but none gained more than 5%. The first bank IPO of 2016, Argentina-based Grupo Supervielle dual listed in New York and Buenos Aires; its...read more
PhaseRx, a preclinical biotech developing treatments for inherited enzyme deficiencies in the liver, raised $19 million by offering 3.7 million shares at $5, the low end of the range of $5 to $7.
PhaseRx plans to list on the Nasdaq under the symbol PZRX....read more
There are four companies set to debut in the week ahead, but only one company with substantial revenue and profit - small-cap Argentinian bank Grupo Supervielle (SUPV). Three additional deals launched and are set to price in May including the...read more
Of the four biotech IPOs that were scheduled to price this week, only two priced successfully. These were the first two biotech IPOs in almost a month, both of which had heavy insider buying.
...read more
US IPO Weekly Recap: A LatAm bank and three minor health care IPOs struggle
The past week saw four IPOs produce insignificant returns. All four deals finished the week at or above the offer price, but none gained more than 5%. The first bank IPO of 2016, Argentina-based Grupo Supervielle dual listed in New York and Buenos Aires; its...read more
Preclinical microcap biotech PhaseRx prices IPO at $5, the low end of the range
PhaseRx, a preclinical biotech developing treatments for inherited enzyme deficiencies in the liver, raised $19 million by offering 3.7 million shares at $5, the low end of the range of $5 to $7. PhaseRx plans to list on the Nasdaq under the symbol PZRX....read more
US IPO Week ahead: Four more IPOs set up May 2016 to be most active month YTD
There are four companies set to debut in the week ahead, but only one company with substantial revenue and profit - small-cap Argentinian bank Grupo Supervielle (SUPV). Three additional deals launched and are set to price in May including the...read more
US IPO Weekly Recap: Biotechs get pushback, but gene editing still soars
Of the four biotech IPOs that were scheduled to price this week, only two priced successfully. These were the first two biotech IPOs in almost a month, both of which had heavy insider buying. ...read more